Copyright © Inderes 2011 - present. All rights reserved.
Log ind for at modtage meddelelser.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Spago Nanomedical

0,254SEK
Vær den første som følger denne virksomhed
spagonanomedical.se/investor-relations

Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.

Omsætning
1,05 mio.
EBIT %
-3.759,05 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPAGO
Daglig lav / høj pris
-
Markedsværdi
23,1 mio. SEK
Aktieomsætning
-
Volumen
-

Major Owners
Source: Millistream Market Data AB

OwnerCapitalVotes
Peter Lindell20,3 %20,3 %
Avanza Pension6,9 %6,9 %
Premium
Not activated

This content is for our Premium customers only.

Sign inLearn more
ViserAlle indholdstyper
Selskabsmeddelelse
27.11.2023

Spago Nanomedical announces outcome of the rights issue

Spago Nanomedical

Pressemeddelelse
23.11.2023

Last day of the subscription period in Spago Nanomedical’s rights issue

Spago Nanomedical

Pressemeddelelse
14.11.2023

Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2024

Spago Nanomedical

Pressemeddelelse
09.11.2023

The subscription period in Spago Nanomedical’s rights issue begins today

Spago Nanomedical

Selskabsmeddelelse
07.11.2023

Spago Nanomedical publishes prospectus in connection with forthcoming rights issue

Spago Nanomedical

Selskabsmeddelelse
03.11.2023

Spago Nanomedical interim report January-September 2023

Spago Nanomedical

Selskabsmeddelelse
31.10.2023

Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB on 31 October 2023

Spago Nanomedical

Pressemeddelelse
30.10.2023

Spago: BioStock: Tumorad's potential in transforming cancer care

Spago Nanomedical

Pressemeddelelse
24.10.2023

Spago Nanomedical applies for extended patent protection for Tumorad®

Spago Nanomedical

Pressemeddelelse
23.10.2023

BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa

Spago Nanomedical

Selskabsmeddelelse
19.10.2023

Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia

Spago Nanomedical

Selskabsmeddelelse
05.10.2023

Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)

Spago Nanomedical

Selskabsmeddelelse
05.10.2023

Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad

Spago Nanomedical

Pressemeddelelse
01.08.2023

Redeye: Spago Nanomedical Q2 - Milestone almost concluded, continued cost control crucial

Spago Nanomedical

Selskabsmeddelelse
31.07.2023

Spago Nanomedical interim report January-June 2023

Spago Nanomedical

Pressemeddelelse
29.06.2023

BioStock: Spago Nanomedical's SAB on Tumorad's potential

Spago Nanomedical

Pressemeddelelse
28.06.2023

Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02

Spago Nanomedical

Pressemeddelelse
13.06.2023

Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board

Spago Nanomedical

Pressemeddelelse
30.05.2023

BioStock: Spago Nanomedical's CDO on study submission

Spago Nanomedical

Pressemeddelelse
23.05.2023

Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study

Spago Nanomedical

Forbinder investorer og virksomheder

Vores sociale mål er at demokratisere information på de finansielle markeder, så alle har lige muligheder for at investere og spare op til deres egen fremtid.

Tag kontakt
  • mie@hcandersencapital.dk
  • +45 28 74 66 40
  • Bredgade 23B, 2. sal
    1260 København K
  • Om os
  • Servicevilkår
  • Privatlivspolitik
  • Ansvarsfraskrivelse for research
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.